Scientific Session 5
CMI-P-21
Yongseok Choi
Korea University
Professor
South Korea
-
Medicinal chemistry, Autoimmune diseases, Fibrosis
B.S., 1992, Seoul National University; Ph.D., 2000, Georgia University (advisor: Chung K. Chu); Postdoctoral Training, 2000-2004, National Cancer Institute (advisor: Victor E. Marquez); Principal Investigator, 2004-2006, Korea Research Institute of Biosciences and Biotechnology, Assistant Professor, 2006-2011, Korea University, Associate Professor (Tenured), 2011-2016, Korea University, Professor, 2016-present, Korea University
NADPH Oxidase Inhibition Promotes Brain Resilience by Attenuating Tauopathy and Neuroinflammation in Alzheimer's Disease. Advanced Science, 2025, in press.
Natural products as IL-6 inhibitors for inflammatory diseases: Synthetic and SAR perspective. Medicinal Research Review, 2024, 44(4), 1683
Perspective for Discovery of Small Molecule IL-6 Inhibitors through Study of Structure–Activity Relationships and Molecular Docking. Journal of Medicinal Chemistry, 2023, 66(7), 4417
Discovery of a novel BLT2 antagonist for the treatment of inflammatory airway diseases. European Journal of Medicinal Chemistry, 2023, 261, 115864
Discovery of a NADPH oxidase inhibitor, (E)-3-cyclohexyl-5-(4-((2-hydroxyethyl)(methyl)amino) benzylidene)-1-methyl-2-thioxoimidazolidin-4-oneone, as a novel therapeutic for Parkinson's disease. European Journal of Medicinal Chemistry, 2022, 244(5), 114854
AIMP2-DX2 provides therapeutic interface to control KRAS-driven tumorigenesis. Nature Communications, 2022, 13(1), 2572
Research in our laboratory focuses on the discovery and development of novel therapeutic agents for autoimmune diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease. Our compound library contains over 3,000 chemical entities available for collaborative research. The laboratory is part of Korea’s National Research Lab 2.0 program and currently offers openings for postdoctoral fellows and doctoral students.
